An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels

被引：23
|
作者：
Roesner, Thies [1 ,2 ]
Derer, Stefanie [1 ,2 ]
Kellner, Christian [1 ,2 ]
Dechant, Michael [2 ,3 ]
Lohse, Stefan [1 ,2 ]
Vidarsson, Gestur [4 ,5 ]
Peipp, Matthias [1 ,2 ]
Valerius, Thomas [1 ,2 ]
机构：
[1] Univ Kiel, Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Univ Kiel, Dept Med Nephrol & Hypertens 4, Kiel, Germany
[4] Sanquin Res, Dept Expt Immunohaematol, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 161卷 / 02期
关键词：
rituximab; IgG3; complement-dependent cytotoxicity; chronic lymphocytic leukaemia; MONOCLONAL-ANTIBODIES; LYMPHOMA;
D O I：
10.1111/bjh.12209
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：282 / 286
页数：5
相关论文
共 32 条
  • [21] Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca2+mobilization and cytotoxicity in human NK cells
    Freitas Monteiro, Marta
    Papaserafeim, Maria
    Real, Aline
    Puga Yung, Gisella L.
    Seebach, Jorg D.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2020, 108 (04) : 1409 - 1423
  • [22] Anti-CD20 rituximab IgG1, IgG3 and IgG4 but not IgG2 subclass differentially trigger Ca2+mobilization and cytotoxicity in human NK cells
    Monteiro, M. Freitas
    Papaserafeim, M.
    Real, A.
    Yung, G. L. Puga
    Seebach, J. D.
    SWISS MEDICAL WEEKLY, 2021, 151 : 25S - 26S
  • [23] Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
    Sue Ellen Verbrugge
    Marjon Al
    Yehuda G Assaraf
    Denise Niewerth
    Johan van Meerloo
    Jacqueline Cloos
    Michael van der Veer
    George L Scheffer
    Godefridus J Peters
    Elena T Chan
    Janet L Anderl
    Christopher J Kirk
    Sonja Zweegman
    Ben AC Dijkmans
    Willem F Lems
    Rik J Scheper
    Tanja D de Gruijl
    Gerrit Jansen
    Experimental Hematology & Oncology, 2 (1)
  • [24] Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
    Verbrugge, Sue Ellen
    Al, Marjon
    Assaraf, Yehuda G.
    Niewerth, Denise
    van Meerloo, Johan
    Cloos, Jacqueline
    van der Veer, Michael
    Scheffer, George L.
    Peters, Godefridus J.
    Chan, Elena T.
    Anderl, Janet L.
    Kirk, Christopher J.
    Zweegman, Sonja
    Dijkmans, Ben A. C.
    Lems, Willem F.
    Scheper, Rik J.
    de Gruijl, Tanja D.
    Jansen, Gerrit
    EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2013, 2
  • [25] Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity
    Buettner, Ralf
    Huang, Mei
    Gritsko, Tanya
    Karras, Jim
    Enkemann, Steve
    Mesa, Tania
    Nam, Sangkil
    Yu, Hua
    Jove, Richard
    MOLECULAR CANCER RESEARCH, 2007, 5 (08) : 823 - 832
  • [26] Decreased interleukin-35 levels and CD4+EBI3+ T cells in patients with type 1 diabetes and the effects of the antibody against CD20 (rituximab)
    Ouyang, Han
    Wen, Jian
    Song, Kai
    ARCHIVES OF MEDICAL SCIENCE, 2021, 17 (01) : 258 - 261
  • [27] rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
    Ge, Xiaowen
    Wu, Lin
    Hu, Weiguo
    Fernandes, Stacey
    Wang, Chun
    Li, Xu
    Brown, Jennifer R.
    Qin, Xuebin
    CLINICAL CANCER RESEARCH, 2011, 17 (21) : 6702 - 6711
  • [28] Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo
    Yamada, Reiko E.
    Steward, Kristopher K.
    Ngarmchamnanrith, Gataree
    Khare, Sanjay
    Sachdev, Raj
    Grewal, Iqbal
    Morrison, Sherie
    Timmerman, John M.
    BLOOD, 2011, 118 (21) : 1171 - 1172
  • [29] Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
    Pawluczkowycz, Andrew W.
    Beurskens, Frank J.
    Beum, Paul V.
    Lindorfer, Margaret A.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    Taylor, Ronald P.
    JOURNAL OF IMMUNOLOGY, 2009, 183 (01): : 749 - 758
  • [30] Comparative in-Vitro Efficacy of CD20xCD3 IgG Bispecific Biosimilar Constructs Against Diffuse Large B Cell Lymphoma (DLBCL) Cell Lines with Different Levels of Expression of CD20
    Bray, Joshua S.
    Thomas, Gethin R.
    Smith, Victoria M.
    Jayne, Sandrine
    Dyer, Martin J. S.
    Walter, Harriet S.
    BLOOD, 2024, 144 : 5826 - 5827
1234